Dunhill Financial’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.02M Buy
4,061
+187
+5% +$40.2K 0.21% 52
2026
Q1
$843K Sell
3,874
-24
-0.6% -$5.32K 0.2% 50
2025
Q4
$891K Buy
3,898
+24
+0.6% +$5.47K 0.22% 47
2025
Q3
$897K Buy
3,874
+147
+4% +$29.9K 0.23% 47
2025
Q2
$692K Buy
3,727
+3,182
+584% +$591K 0.2% 51
2025
Q1
$114K Sell
545
-336
-38% -$65.3K 0.05% 126
2024
Q4
$156K Buy
881
+171
+24% +$31.4K 0.07% 103
2024
Q3
$140K Buy
710
+473
+200% +$88.3K 0.07% 99
2024
Q2
$40.7K Buy
237
+39
+20% +$6.46K 0.03% 156
2024
Q1
$36.1K Buy
198
+30
+18% +$5.17K 0.03% 132
2023
Q4
$26.1K Buy
+168
New +$24.5K 0.02% 137

Other funds holding ABBV

Dunhill Financial's ABBV Position: Q2 2026 in Review

Dunhill Financial increased its AbbVie (ABBV) stake by 4.8% in Q2 2026, buying an estimated $40.2K and bringing the position to 4,061 shares worth $1.02M. The position accounts for 0.21% of the portfolio, ranked #52.

Dunhill Financial first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Dunhill Financial held 4,061 shares of AbbVie worth $1.02M as of Q2 2026.
  • Dunhill Financial bought 187 AbbVie shares in Q2 2026, an estimated $40.2K.
  • AbbVie made up 0.21% of Dunhill Financial's portfolio in Q2 2026, its #52 holding.
  • Dunhill Financial first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.